Biomind Labs Announces Filing of Continuous Disclosure Documents and Appointment of Scott Ackerman to the Board

Executive Summary

• Biomind Labs Inc. has filed amended and restated continuous disclosure documents (MD&A and officers' certificates) for fiscal years and quarters ending December 31, 2024, March 31, 2025, June 30, 2025, and September 30, 2025, following a corrective disclosure request by the Ontario Securities Commission (OSC).
• The company has appointed Scott Ackerman as an independent director and Audit Committee member.
• The filings resolve the conditions of a cease trade order (FFCTO) issued on April 4, 2025, due to the company's failure to file required audited financial statements and other documents for the year ended December 31, 2024.

Key Details

• Regulatory Context: The amendments were prepared in response to a staff review by the Ontario Securities Commission. The company was previously subject to a cease trade order issued April 4, 2025, for failing to file audited financials, MD&A, officers' certificates, and the annual information form for the year ended December 31, 2024.
• Filing Details:
  • Amended & restated MD&A and officers' certificates for the year ended December 31, 2024.
  • Amended & restated MD&A and officers' certificates for the three months ended March 31, 2025.
  • Amended & restated MD&A and officers' certificates for the six months ended June 30, 2025.
  • Interim unaudited financial statements, MD&A, and officers' certificates for the nine months ended September 30, 2025.
  • Annual information form for the year ended December 31, 2024.
  • Form 51-102F6 - Statement of Executive Compensation.
• Amendment Content: The amended MD&As include enhancements and clarifications regarding the company's business operations and drug candidate programs. They provide detailed results of operations compared to comparative periods, quantifying material contributing factors to period-over-period variances. The 2024 annual MD&A also includes added audit committee and corporate governance disclosure.
• Director Appointment: Scott Ackerman was appointed as an independent director of the Board and an independent member of the Audit Committee. He is the CEO of Emprise Capital Corp., a private merchant bank specializing in restructuring services for public companies, and serves as a director, senior officer, and audit committee chair for several Canadian listed public companies.
• Compliance Timeline: The filings cover periods that came due on May 15, 2025 (Q1), May 20, 2025 (Q2), August 14, 2025 (Q3), and November 14, 2025 (Q9), while the FFCTO was still in effect.

Notable Quotes

• No direct quotes from the CEO or President were included in the text of the release.